Eli Lilly and Company (LLY)
LLY · Health Care · 
United States
Eli Lilly and Company (LLY) is a US company in the Health Care sector. Eli Lilly develops and sells prescription medicines. Its fastest-growing products in recent years have been the diabetes and weight-loss treatments Mounjaro and Zepbound, both based on the active ingredient tirzepatide. Other areas include oncology, immunology and neuroscience, where the Alzheimer's treatment Kisunla received US approval in 2024. Lilly was founded in 1876 and is based in Indianapolis, Indiana.
The stock has its largest weight in XUHL (MSCI USA Health Care), at 16.40%. Anyone who holds an ETF containing Eli Lilly and Company also has an indirect stake in the company.
Data and Charts: Eli Lilly and Company
Key Data for Eli Lilly and Company
Eli Lilly and Company Stock Price Chart
The Eli Lilly and Company chart shows daily closing prices and is set to the current year by default. The stock is up 31.9% year to date and up 67.9% over twelve months. The last recorded close on October 30, 2026, was $1,417.54, at 100% of the 52-week range.
Price series from our database since Jul 11, 2024, 580 daily values.
Eli Lilly and Company Stock Performance
| Year to date | +31.9% | 1 year | +67.9% |
|---|---|---|---|
| 1 month | +22.5% | 3 months | +23.4% |
| Calendar year 2025 | +39.2% |
Measured in euros, Eli Lilly and Company is up 38.7% year to date and up 73.5% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: Eli Lilly and Company
What ETF Is Eli Lilly and Company In?
Eli Lilly and Company has above-average ETF coverage and is held by 22 of the 104 ETFs we track, which together follow 11 indices. That puts the stock in more ETFs than 85.1% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| XUHL / XUHC | MSCI USA Health Care | 16.40% | €163.97 |
| SPFS | MSCI World Health Care | 12.14% | €121.37 |
| XDWH | MSCI World Health Care | 12.12% | €121.23 |
| XDEQ | MSCI World Quality | 2.94% | €29.36 |
| SPYL / SPY5 | S&P 500 | 1.65% | €16.52 |
| SXR8 | S&P 500 | 1.65% | €16.50 |
| XD9U / XD9D | MSCI USA | 1.65% | €16.48 |
| SWWD | MSCI World | 1.21% | €12.11 |
| SPPW | MSCI World | 1.21% | €12.11 |
| XDWD / XDWL | MSCI World | 1.21% | €12.06 |
| EUNL | MSCI World | 1.20% | €12.00 |
| WIMI | MSCI World IMI | 1.08% | €10.80 |
| SPYY | MSCI ACWI | 1.08% | €10.75 |
| IUSQ | MSCI ACWI | 1.07% | €10.70 |
| SPYI / SPSA | MSCI ACWI IMI | 0.94% | €9.38 |
| XDEB | MSCI World Minimum Volatility | 0.40% | €4.02 |
| XDEW | S&P 500 Equal Weight | 0.24% | €2.38 |
The last column shows how much of €1,000 in one of these funds goes to Eli Lilly and Company, based on each fund's latest holdings list.
US-listed ETFs holding Eli Lilly and Company (weight per latest SEC filing): VUG 2.81%, IVV 1.47%, SPY 1.47%, VOO 1.47%, VTI 1.40%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
Eli Lilly and Company Weight in iShares Core MSCI World (EUNL) Since 2019
In iShares Core MSCI World (EUNL), Eli Lilly and Company had a weight of 0.24% on Sep 30, 2019 and 1.20% on Oct 29, 2026. The fund tracks the MSCI World. That is also the stock's highest weight in the period shown. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much Eli Lilly and Company overlaps with the rest of a portfolio.
Which Tracked Investors Hold Eli Lilly and Company?
Eli Lilly and Company is not among the largest purchases in the quarter ending Jun 30, 2026. The list is led by GOOGL, DAL and NEBIUS GROUP N.V. Of the 3 tracked managers holding the stock, 1 added and 1 cut.
| Investor | Shares | Value | Quarter |
|---|---|---|---|
| Bridgewater Associates | 87,023 | $104M | increased by 16,211 |
| Soros Fund Management | 22,199 | $27M | unchanged |
| Duquesne Family Office | 12,380 | $15M | reduced by 88,295 |
As of Jun 30, 2026. Based on quarterly filings with the US securities regulator, submitted up to 45 days after the reference date. The change counts shares, not price gains.
Stocks With ETF Exposure Similar to Eli Lilly and Company
| Stock | Shared ETFs | r | 1 year | Annualized volatility | Net margin | Revenue growth |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | – | – | +67.9% | 38.0% | 31.7% | +44.7% |
 McKesson Corporation | 21 | – | +20.5% | 28.4% | 1.2% | +12.4% |
 ResMed | 21 | – | -8.8% | 28.8% | 26.9% | +9.9% |
 Edwards Lifesciences Corporation | 21 | – | +10.2% | 25.0% | 17.7% | +11.5% |
 HCA Healthcare Inc | 21 | – | +1.4% | 29.0% | 9.0% | +7.1% |
 AbbVie | 21 | +0.65 | +29.2% | 26.5% | 6.9% | +8.6% |
 Abbott Laboratories | 21 | – | -14.8% | 24.0% | 14.7% | +5.7% |
 Cardinal Health | 21 | – | +31.9% | 26.3% | 0.7% | +14.2% |
 Cencora | 21 | – | -3.0% | 26.1% | 0.5% | +9.3% |
These stocks reach a portfolio through largely the same funds as Eli Lilly and Company. “Shared ETFs” counts the funds that hold both.
Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.
Fundamental Analysis: Eli Lilly and Company
Eli Lilly and Company Key Financials
Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025).
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| FY ended Dec 2023 | 34.1 | 5.2 | 15.4% |
| FY ended Dec 2024 | 45.0 | 10.6 | 23.5% |
| FY ended Dec 2025 | 65.2 | 20.6 | 31.7% |
Latest Patents Granted to Eli Lilly
In the 52 weekly issues of the US patent office from Nov 4, 2025 to Oct 27, 2026, Eli Lilly received 69 utility patents and 16 design patents. That is 0.022% of all utility patents the US patent office granted in those weeks. The median time from filing to grant was 4.5 years.
| Granted | Patent | Title | Filed | Technology field |
|---|---|---|---|---|
| US 12770737 B2 | Physiological data monitoring system | G16H Healthcare informatics | ||
| US 12767714 B2 | LAG-3 and PD-1/LAG-3-antibodies | C07K Chemistry; metallurgy | ||
| US 12741999 B2 | Incretin analogs and uses thereof | C07K Chemistry; metallurgy | ||
| US 12735433 B2 | Macrocyclic glucagon-like peptide 1 receptor agonists | C07D Chemistry; metallurgy | ||
| US 12723063 B2 | GIPR-agonist compounds | C07K Chemistry; metallurgy |
These are grants, not applications. The office usually publishes an application 18 months after the priority date; the grant tends to come much later. Owners counted: Eli Lilly and Company. Titles as published by the office; median time based on 35 patents with a known filing date.
The patent screener lists more grants, filterable by company, type and technology field. The M&A and patents page compares companies.
Technical Analysis: Eli Lilly and Company
Eli Lilly and Company Risk Metrics
The close on Oct 30, 2026, was the highest since our series began on Jul 11, 2024. When the S&P 500 rose or fell 1%, Eli Lilly and Company moved 0.19% on average in the same direction (past 252 trading days). The correlation of 0.07, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Eli Lilly and Company.
What Eli Lilly and Company Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| Astrazeneca plc | +0.67 | |
| Johnson & Johnson | +0.66 | |
| AbbVie Inc. | +0.65 | |
| Pfizer Inc. | +0.63 | |
| Royalty Pharma Plc Class A | +0.63 | |
| Vertex Pharmaceuticals Incorporated | +0.62 | |
| Keysight Technologies Inc | -0.53 | |
| Qnity Electronics Inc. | -0.48 | |
| Texas Instruments Incorporated | -0.48 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
